Table 3. Comparison of serum autoantibody levels among groups (MFI).
| Characteristic | Controls | Eosinophilic COPD | Non-eosinophilic COPD | P |
|---|---|---|---|---|
| Anti-La_IgG | 6,221.2 (4,624.8–7,555.75) | 5,339.2 (4,137.63–6,964.13) | 4,438.7 (3,969.25–6,794.55) | 0.496 |
| Anti-Aβ_IgG | 190.55 (166.05–246.15) | 130.8 (112.48–176.05)a | 140.75 (113.23–223.28) | 0.041 |
| Anti-HSP70_IgG | 15,411.1 (14,022.68–21,512.35) | 11,579.4 (8,560.05–19,350.28)a | 13,647.25 (10,810.45–15,869.08) | 0.042 |
| Anti-Elastin_IgG | 1,225.7 (1,068–1,512.18) | 1,153.15 (966.38–1,385.28) | 1,108.55 (930.68–1,404.13) | 0.526 |
| Anti-CENPB_IgG | 8,281.65 (3,411.08–19,562.88) | 4,739.7 (2,956.08–9,470.33) | 4,696.75 (2,743.3–5,707.58) | 0.266 |
| Anti-Cytokeratin18_IgG | 9,021.35 (4,346.15–11,326.1) | 4,519.35 (2,506.8–8,855.38) | 5,140.75 (1,499.5–13,820.9) | 0.259 |
| Anti-CollagenI_IgG | 483.5 (372.95–562.95) | 337.8 (246.2–523.68) | 434.35 (299.4–510.33) | 0.236 |
| Anti-CytochromeC_IgG | 1,666.35 (1,135.68–2,959.6) | 1,348.5 (972.33–2,167.98) | 1,604.35 (1,265.98–2,321.7) | 0.334 |
| Anti-CollagenII_IgG | 2,891.3 (2,231.68–4,003.73) | 2,080.55 (1,528.68–2,890.25) | 2,262.3 (1,521.85–5,055.28) | 0.084 |
| Anti-HSP47_IgG | 2,432.15 (1,985.73–2,853.38) | 1,574.7 (1,260.5–2,132.43)a | 1,828.8 (1,188.93–2,675.7) | 0.016 |
| Anti-CollagenIV_IgG | 2,392 (1,119.5–4,302.13) | 1,820.25 (1,188–4,264.65) | 2,102.2 (1,196.23–2,916.65) | 0.765 |
| Anti-Vimentin_IgG | 637.2 (481.6–871.95) | 620 (476.88–971.38) | 587.85 (449.93–1241.35) | 0.898 |
| Anti-Aggrecan_IgG | 977.6 (853.35–1,132.98) | 848.65 (714.1–980.35) | 859.95 (705.3–1,020.93) | 0.115 |
| Anti-La_IgM | 12,636.45 (8,738.75–18,968.43) | 16,811.5 (9,505.63–29,345) | 12,625.6 (8,631.45–62,355.48) | 0.537 |
| Anti-Aβ_IgM | 29.05 (0–112.85) | 1.2 (0–128.28) | 50.85 (3.15–194.23) | 0.539 |
| Anti-HSP70_IgM | 21,452.3 (14,324.95–26,854.25) | 26,795.85 (16,977.33–52,042.03) | 23,091.25 (12,759.08–51,967.13) | 0.269 |
| Anti-Elastin_IgM | 7,717.45 (5,376.68–9,516.75) | 8,761.5 (6,274.98–9,924.8) | 9,450.95 (7,026.9–11,096.2) | 0.295 |
| Anti-CENPB_IgM | 9,855.3 (3,635.25–15,711.73) | 14,348.8 (7,156.98–21,443.98) | 12,890.65 (7,533.25–18,341.63) | 0.170 |
| Anti-Cytokeratin18_IgM | 9,358.75 (2,772.83–23,725.4) | 6,341.05 (3,100.88–12,749.48) | 7,426.05 (2,787.03–12463.63) | 0.744 |
| Anti-CollagenI_IgM | 1,247.4 (670.78–2,744.75) | 1,190.75 (798.25–2,783.53) | 2,039.4 (1,019.1–3,504.98) | 0.493 |
| Anti-CytochromeC_IgM | 12,505.65 (7,984.85–17,158) | 13,876.55 (11,272.73–20,962.08) | 15,671.4 (12,190.4–25,479.4) | 0.380 |
| Anti-CollagenII_IgM | 4,853.3 (2,308.1–12,439.78) | 4,562.25 (2,564.7–13,761.33) | 6,686.4 (3,398.78–14,378.85) | 0.697 |
| Anti-HSP47_IgM | 4,409.05 (1,305.28–6,667.53) | 2,229.75 (1,308.7–5,158.5) | 2419.2 (1,384.08–3,770.83) | 0.495 |
| Anti-CollagenIV_IgM | 1,813.65 (37.2–7,620.38) | 1,883.65 (107.55–5,536.8) | 1,842.4 (172.28–3,763.83) | 0.870 |
| Anti-Vimentin_IgM | 1,762.9 (900.38–11,814.18) | 3,049.4 (1,587.85–7,395.8) | 5,056.6 (1,510.58–21,145.65) | 0.277 |
| Anti-Aggrecan_IgM | 1.1 (0–1,389.63) | 1.2 (0–437.85) | 0 (0–32.7) | 0.099 |
Eosinophilic COPD is defined as ≥3% sputum eosinophils, and non-eosinophilic COPD is defined as <3% sputum eosinophils. Aβ: amyloid-beta; MFI: mean fluorescence intensity; HSP47: heat shock protein 47; HSP70: heat shock protein 70; La: La/Sjögren syndrome type B antigen; CENP-B; centromere protein B. aP<0.05 vs. control group.